The original article can be found online at https://doi.
In the original publication, Table 2 note was incorrectly published as ''*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/ 1.73 m 2 . Individuals already treated with canagliflozin or empagliflozin who demonstrate renal decline may continue treatment until eGFR reaches\45 mL/min/1.73 m 2 ''.
The correct text should read as ''*SGLT2i therapies may be initiated in people with eGFR 60 mL/min/1.73 m 2 . Individuals already treated with an SGLT2i therapy who demonstrate renal decline may continue treatment until eGFR reaches \ 45 mL/min/1.73 m 2 .'' Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
